Skip to main content

Table 4 Pregnancy rates

From: Safety and efficacy of Ovaleap® (recombinant human follicle-stimulating hormone) for up to 3 cycles in infertile women using assisted reproductive technology: a phase 3 open-label follow-up to Main Study

  

Previous Treatment in Main Study

 

Total Group

Ovaleap®

Gonal-f®

Cycle 2

   

 Biochemical pregnancy, n/N (%)

46/147 (31.0)

24/80 (30.0)

22/67 (32.8)

 Ongoing pregnancya, n/N (%)

37/143 (25.9)

21/79 (26.6)

16/64 (25.0)

Cycle 3

   

 Biochemical pregnancy, n/N (%)

19/61 (31.0)

10/34 (29.4)

9/27 (33.3)

 Ongoing pregnancya, n/N (%)

13/60 (21.7)

8/33 (24.2)

5/27 (18.5)

Combined Cycles 2 and 3

   

 Biochemical pregnancy, n/N (%)

63/147 (42.9)

33/80 (41.3)

30/67 (44.8)

 Ongoing pregnancya, n/N (%)

50/144 (34.7)

29/80 (36.3)

21/64 (32.8)

  1. a N includes only those patients with embryo transfer